Dec 05, 2016 7:05am EST Matinas BioPharma Commences Dosing in Phase 1 Study of Orally Administered Aminoglycoside Antibiotic MAT2501
Nov 21, 2016 7:05am EST Matinas BioPharma Initiates Enrollment and Commences Patient Dosing in Phase 2 Study of MAT2203 for the Treatment of Vulvovaginal Candidiasis
Nov 15, 2016 7:05am EST Matinas BioPharma Reports 2016 Third Quarter Financial Results and Provides Corporate Update
Nov 03, 2016 7:35am EDT Matinas BioPharma Researchers Among Rutgers University Recipients of 2016 Edison Patent Awards
Oct 26, 2016 7:35am EDT Matinas BioPharma Presents Preclinical Data of Orally Administered Encochleated Influenza Vaccine in Murine Model at IDWeek 2016
Oct 24, 2016 7:05am EDT Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology
Oct 13, 2016 7:05am EDT Matinas BioPharma to Present at the 2nd Annual Dawson James Securities Growth Stock Conference
Sep 28, 2016 7:00am EDT Matinas BioPharma Commences Patient Dosing in NIH-Sponsored Phase 2a Study with Lead Anti-Infective Candidate MAT2203
Sep 07, 2016 7:05am EDT Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Prophylaxis of Invasive Fungal Infections by U.S. FDA
